TGCT Support
  • Home
  • About TGCT
    • Causes of TGCT
    • Types of TGCT
    • Tumor Location
    • TGCT in Pediatrics
    • Diagnosis >
      • Biopsy
      • Imaging Features
  • Treatment
    • Surgery >
      • Recovery >
        • Surgery Guide
    • Medications >
      • Turalio >
        • Recommended Dosing
      • Romvimza
      • Imatinib
      • Common Side Effect of TGCT Drugs
    • Clinical Trials >
      • AMB-05X
      • Pimicotinib
      • Emactuzumab
      • Cabiralizumab
      • Lacnotuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Consensus Guideline
    • Our Research
    • Nutrition
    • Pain Management
    • Mental Health >
      • Find Mental Health Help
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
    • FAQs
  • News
    • Events
    • Patient Stories
  • About Us
    • Meet the Team
    • Medical Advisory Board
    • Partners >
      • TGCT Support France
    • Contact Us
    • Our Store
  • DONATE
    • GEM Program
  • Home
  • About TGCT
    • Causes of TGCT
    • Types of TGCT
    • Tumor Location
    • TGCT in Pediatrics
    • Diagnosis >
      • Biopsy
      • Imaging Features
  • Treatment
    • Surgery >
      • Recovery >
        • Surgery Guide
    • Medications >
      • Turalio >
        • Recommended Dosing
      • Romvimza
      • Imatinib
      • Common Side Effect of TGCT Drugs
    • Clinical Trials >
      • AMB-05X
      • Pimicotinib
      • Emactuzumab
      • Cabiralizumab
      • Lacnotuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Consensus Guideline
    • Our Research
    • Nutrition
    • Pain Management
    • Mental Health >
      • Find Mental Health Help
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
    • FAQs
  • News
    • Events
    • Patient Stories
  • About Us
    • Meet the Team
    • Medical Advisory Board
    • Partners >
      • TGCT Support France
    • Contact Us
    • Our Store
  • DONATE
    • GEM Program

AMB-05X

AMB-05x

AMB-05X (AmMax Bio, Inc.) previously enrolled for a Phase 2 clinical trial on a monoclonal antibody local injection for the treatment of TGCT of the knee. This means a man-made protein is locally injected into the joint to block the growth and recruitment of other cells, leading to tumor shrinkage. The injection is ultrasound guided, like shown.

In the Phase 2 trial, the trial intended to evaluate the safety, toxicity, effectiveness, and tolerability of 150mg AMB-05X as a 24 week treatment every 4 weeks (Part 1), and a treatment/observation period for 72 weeks where different durations between injections will be studied, with an additional 2 week follow-up. The trial was closed prematurely and no status update has been provided. 

AMB-05X is administered as a joint injection to the knee for 24 weeks (1 injection every 4 weeks, 6 injections total). In Part 2, the injection may be given every 4, 6, 8, and 12 weeks in 12 week cycles (injections every 4 weeks for 12 weeks [3 total], injections every 6 weeks for 12 weeks [2 total], etc). AMB-05X uses a monoclonal antibody that is designed to target CSF1 and block it from signaling to TGCT and surrounding cells. 

For more information, visit the clinical trial website for AMB-05X or ask your healthcare provider.



Picture
AMB-05X Patient Support Group

TGCT SUPPORT IS A PROGRAM OF THE LIFE RAFT GROUP

Picture
155 US Highway 46, Suite 202                      Wayne, NJ 07470                      [email protected]